Signify Bio Secures Initial Financing

Signify Bio, a trailblazing biotech company developing in situ protein therapeutics, has announced an oversubscribed initial financing round. Led by Actium Group, the round included strategic investors such as the Gates Foundation Strategic Investment Fund, Danaher Ventures, Eli Lilly and Company, and BrightEdge, the American Cancer Society’s venture capital arm. Built on three proprietary platforms, Signify Bio is advancing non-viral delivery systems and nucleic acid payloads to enable targeted protein production within the human body.

Learn more